APA (7th ed.) Citation

Seymour, J. F., Kipps, T. J., Eichhorst, B., Hillmen, P., D’Rozario, J., Assouline, S., . . . Kater, A. P. (2018). Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. The New England journal of medicine, 378(12), 1107-1120. https://doi.org/10.1056/NEJMoa1713976

Chicago Style (17th ed.) Citation

Seymour, John F., et al. "Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia." The New England Journal of Medicine 378, no. 12 (2018): 1107-1120. https://doi.org/10.1056/NEJMoa1713976.

MLA (9th ed.) Citation

Seymour, John F., et al. "Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia." The New England Journal of Medicine, vol. 378, no. 12, 2018, pp. 1107-1120, https://doi.org/10.1056/NEJMoa1713976.